1. Siegel R.L. et al. Cancer statistics 2015. CA Cancer J Clin 2015; 65: 5.

2. Soria F. et al. Epidemiology diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol 2017; 35: 379.

3. Margulis V. et al. Outcomes of radical nephroureterectomy a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 2009; 115: 1224.

4. Shariat S.F. et al. Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma. World J Urol 2011; 29: 481.

5. Roupret M. et al. Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (Lynch syndrome) tumor spectrum. Eur Urol 2008; 54: 1226.

6. Acher P. et al. Towards a rational strategy for the surveillance of patients with Lynch syndrome (hereditary non-polyposis colon cancer) for upper tract transitional cell carcinoma. BJU Int 2010; 106: 300.

7. Matin S.F. et al. Misclassification of Upper Tract Urothelial Carcinoma in Patients with Lynch Syndrome. JAMA Oncol 2018; 4: 1010.

8. Therkildsen C. et al. Molecular subtype classification of urothelial carcinoma in Lynch syndrome. Mol Oncol 2018; 12: 1286.

9. Colin P. et al. Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract. BJU Int 2009; 104: 1436.

10. Crivelli J.J. et al. Effect of smoking on outcomes of urothelial carcinoma a systematic review of the literature. Eur Urol 2014; 65: 742.

11. Cosyns J.P. Aristolochic acid and "Chinese herbs nephropathy": a review of the evidence to date. Drug Saf 2003; 26: 33.

12. Grollman A.P. Aristolochic acid nephropathy: Harbinger of a global iatrogenic disease. Environ Mol Mutagen 2013; 54: 1.

13. Rosenquist T.A. et al. Mutational signature of aristolochic acid: Clue to the recognition of a global disease. DNA Repair (Amst) 2016; 44: 205.

14. Jelakovic B. et al. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. Kidney Int 2012; 81: 559.

15. Chen C.H. et al. Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci U S A 2012; 109: 8241.

16. Nortier J.L. et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 2000; 342: 1686.

17. Grollman A.P. Aristolochic acid nephropathy: Harbinger of a global iatrogenic disease. Environ Mol Mutagen 2013; 54: 1.

18. Babjuk M. et al. EAU guidelines on non-muscle-invasive bladder cancer (T1, T1 and CIS). In: EAU guidelines, presented at the 34th EAU Annual Congress. Barcelona: EAU Guidelines Office, 2019.

19. Siegel R.L. et al. Cancer statistics, 2017. CA Cancer J Clin 2017; 66: 7.

20. Munoz J.J. et al. Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J Urol 2000; 164: 1523.

21. Cosentino M. et al. Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma. World J Urol 2013; 31: 141.

22. Xylinas E. et al. Multifocal carcinoma in situ of the upper tract is associated with high risk of bladder cancer recurrence. Eur Urol 2012; 61: 1069.

23. Li W.M. et al. Oncologic outcomes following three different approaches to the distal ureter and bladder cuff in nephroureterectomy for primary upper urinary tract urothelial carcinoma. Eur Urol 2010; 57: 963.

24. Inman B.A., et al. Carcinoma of the upper urinary tract: predictors of survival and competing causes of mortality. Cancer 2009; 115: 2853.

25. Cowan N.C. CT urography for hematuria. Nat Rev Urol 2012; 9: 218.

26. Ito Y. et al. Preoperative hydronephrosis grade independently predicts worse pathological outcomes in patients undergoing nephroureterectomy for upper tract urothelial carcinoma. J Urol 2011; 185: 1621.

27. Raman J.D. et al. Does preoperative symptom classification impact prognosis in patients with clinically localized upper-tract urothelial carcinoma managed by radical nephroureterectomy? Urol Oncol 2011; 29: 716.

28. Reynolds J.P. et al. Comparison of urine cytology and fluorescence in situ hybridization in upper urothelial tract samples. Cancer Cytopathol 2014; 122: 459.

29. Hurel S. et al. Influence of preoperative factors on the oncologic outcome for upper urinary tract urothelial carcinoma after radical nephroureterectomy. World J Urol 2015; 33: 335.

30. Verhoest G. et al. Predictive factors of recurrence and survival of upper tract urothelial carcinomas. World J Urol 2011; 29: 495.

31. Takahashi N. et al. Gadolinium enhanced magnetic resonance urography for upper urinary tract malignancy. J Urol 2010; 183: 1330.

32. Walton T.J. et al. Oncological outcomes after laparoscopic and open radical nephroureterectomy: results from an international cohort. BJU Int 2011; 108: 406.

33. Marchioni M. et al. Impact of diagnostic ureteroscopy on intravesical recurrence in patients undergoing radical nephroureterectomy for upper tract urothelial cancer: a systematic review and meta-analysis. BJU Int 2017; 120: 313.

34. Guo R.Q. et al. Impact of ureteroscopy before radical nephroureterectomy for upper tract urothelial carcinomas on oncological outcomes: a meta-analysis. BJU Int 2018; 121: 184.

35. Bus M.T. et al. Optical diagnostics for upper urinary tract urothelial cancer: technology, thresholds, and clinical applications. J Endourol 2015; 29: 113.

36. Brien J.C. et al. Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. J Urol 2010; 184: 69.

37. Abouassaly R. et al. Troubling outcomes from population-level analysis of surgery for upper tract urothelial carcinoma. Urology 2010; 76: 895.

38. Kata S.G. et al. Photodynamic diagnostic ureterorenoscopy: A valuable tool in the detection of upper urinary tract tumour. Photodiagnosis Photodyn Ther 2016; 13: 255.

39. Matsumoto K. et al. Racial differences in the outcome of patients with urothelial carcinoma of the upper urinary tract: an international study. BJU Int 2011; 108 E304.

40. Singla N. et al. A multi-institutional comparison of clinicopathological characteristics and oncologic outcomes of upper tract urothelial carcinoma in China and the United States. J Urol 2017; 197: 1208.

41. Fajkovic H. et al. Prognostic value of extranodal extension and other lymph node parameters in patients with upper tract urothelial carcinoma. J Urol 2012; 187: 845.

42. Roscigno M. et al. Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer. Eur Urol 2011; 60: 776.

43. Lughezzani G. et al. A critical appraisal of the value of lymph node dissection at nephroureterectomy for upper tract urothelial carcinoma. Urology 2010; 75: 118.

44. Simsir A. et al. Prognostic factors for upper urinary tract urothelial carcinomas: stage, grade, and smoking status. Int Urol Nephrol 2011; 43: 1039.

45. Rink M. et al. Impact of smoking on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy. Eur Urol 2013; 63: 1082.

46. Sundi D. et al. Upper tract urothelial carcinoma: impact of time to surgery. Urol Oncol 2012; 30: 266.

47. Gadzinski A.J. et al. Long-term outcomes of immediate versus delayed nephroureterectomy for upper tract urothelial carcinoma. J Endourol 2012; 26: 566.

48. Lee J.N. et al. Impact of surgical wait time on oncologic outcomes in upper urinary tract urothelial carcinoma. J Surg Oncol 2014; 110: 468.

49. Waldert M. et al. A delay in radical nephroureterectomy can lead to upstaging. BJU Int 2010; 105: 812.

50. Favaretto R.L. et al. Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study. World J Urol 2017; 35: 113.

51. Scarpini S. et al. Impact of the expression of Aurora-A, p53, and MIB-1 on the prognosis of urothelial carcinomas of the upper urinary tract. Urol Oncol 2012; 30: 182.

52. Roupret M. et al. Microsatellite instability as predictor of survival in patients with invasive upper urinary tract transitional cell carcinoma. Urology 2005; 65: 1233.

53. Krabbe L.M. et al. Prognostic value of PD-1 and PD-L1 expression in patients with high grade upper tract urothelial carcinoma. J Urol 2017; 198: 1253.

54. Seisen T. et al. A systematic review and meta-analysis of clinicopathologic factors linked to intravesical recurrence after radical nephroureterectomy to treat upper tract urothelial carcinoma. Eur Urol 2015; 67: 1122.

55. Seisen T. et al. Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the EAU Nonmuscle Invasive Bladder Cancer Guidelines Panel. Eur Urol 2016; 70: 1052.

56. Leow J.J. et al. A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. Eur Urol 2014; 66: 529.

57. Cutress M.L. et al. Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review. BJU Int 2012; 110: 614.

58. Cornu J.N. et al. Oncologic control obtained after exclusive flexible ureteroscopic management of upper urinary tract urothelial cell carcinoma. World J Urol 2010; 28: 151.

59. Jeldres C. et al. Segmental ureterectomy can safely be performed in patients with transitional cell carcinoma of the ureter. J Urol 2010; 183: 1324.

60. Colin P. et al. Comparison of oncological outcomes after segmental ureterectomy or radical nephroureterectomy in urothelial carcinomas of the upper urinary tract: results from a large French multicentre study. BJU Int 2012; 110: 1134.

61. Lopez-Beltran A. et al. Tumours of the urinary system. In: World Health Organization classification of tumors: pathology and genetics of tumours of the urinary system and male genital organs. Eds.: Eble J.N. et al. Lyon: IARC Press, 2004.

62. Irie A. et al. Intravesical instillation of bacille Calmette-Guerin for carcinoma in situ of the urothelium involving the upper urinary tract using vesicoureteral reflux created by a double-pigtail catheter. Urology 2002; 59: 53.

63. Horiguchi H. et al. Impact of bacillus Calmette-Guerin therapy of upper urinary tract carcinoma in situ: comparison of oncological outcomes with radical nephroureterectomy. Med Oncol 2018; 35: 41.

64. Tomisaki I. et al. Efficacy and tolerability of bacillus Calmette-Guerin therapy as the first-line therapy for upper urinary tract carcinoma in situ. Cancer Invest 2018; 36: 152.

65. Yossepowitch O. et al. Assessment of vesicoureteral reflux in patients with self-retaining ureteral stents: implications for upper urinary tract instillation. J Urol 2005; 173: 890.

66. Ong A.M. et al. Trocar site recurrence after laparoscopic nephroureterectomy. J Urol 2003; 170: 1301.

67. Ni S. et al. Laparoscopic versus open nephroureterectomy for the treatment of upper urinary tract urothelial carcinoma: a systematic review and cumulative analysis of comparative studies. Eur Urol 2012; 61: 1142.

68. Ariane M.M. et al. Assessment of oncologic control obtained after open versus laparoscopic nephroureterectomy for upper urinary tract urothelial carcinomas (UUT-UCs): results from a large French multicenter collaborative study. Ann Surg Oncol 2012; 19: 301.

69. Simone G. et al. Laparoscopic versus open nephroureterectomy: perioperative and oncologic outcomes from a randomized prospective study. Eur Urol 2009; 56: 520.

70. Adibi M. et al. Oncological outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: comparison over the three decades. Int J Urol 2012; 19: 1060.

71. Clements M.B. et al. Robotic-assisted surgery for upper tract urothelial carcinoma: a comparative survival analysis. Ann Surg Oncol 2018; 25: 2550.

72. Rodriguez J.F. et al. Utilization and outcomes of nephroureterectomy for upper tract urothelial carcinoma by surgical approach. J Endourol 2017; 31: 661.

73. Aboumohamed A.A., et al. Oncologic outcomes following robot-assisted laparoscopic nephroureterectomy with bladder cuff excision for upper tract urothelial carcinoma. J Urol 2015; 194: 1561.

74. Moschini M. et al. Trends of lymphadenectomy in upper tract urothelial carcinoma (UTUC) patients treated with radical nephroureterectomy. World J Urol 2017; 35: 1541.

75. Zareba P. et al. Association between lymph node yield and survival among patients undergoing radical nephroureterectomy for urothelial carcinoma of the upper tract. Cancer 2017; 123: 1741.

76. Dominguez-Escrig J.L. et al. Potential benefit of lymph node dissection during radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the European Association of Urology Guidelines Panel on Non-muscle-invasive Bladder Cancer. Eur Urol Focus 2019; 5: 224.

77. Giannarini G. et al. Antegrade perfusion with bacillus Calmette-Guerin in patients with non-muscle-invasive urothelial carcinoma of the upper urinary tract: who may benefit? Eur Urol 2011; 60: 955.

78. Herr H.W. Extravesical tumor relapse in patients with superficial bladder tumors. J Clin Oncol 1998; 16: 1099.

79. Matin S.F. et al. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer 2010; 116: 3127.

80. Liao R.S. et al. Comparison of pathological stage in patients treated with and without neoadjuvant chemotherapy for high risk upper tract urothelial carcinoma. J Urol 2018; 200: 68.

81. Porten S. et al. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer 2014; 120: 1794.

82. Kubota Y. et al. Oncological outcomes of neoadjuvant chemotherapy in patients with locally advanced upper tract urothelial carcinoma: a multicenter study. Oncotarget 2017; 8: 101500.

83. Moschini M. et al. Impact of primary tumor location on survival from the European Organization For The Research And Treatment Of Cancer Advanced Urothelial Cancer Studies. J Urol 2018; 199: 1149.

84. Balar A.V. et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol 2017; 18: 1483.

85. Balar A.V. et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 2017; 389: 67.

86. Heers H. et al. Vinflunine in the treatment of upper tract urothelial carcinoma - subgroup analysis of an observational study. Anticancer Res 2017; 37: 6437.

87. Rosenberg J.E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a singlearm, multicentre, phase 2 trial. Lancet 2016; 387: 1909.

88. Powles T. et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomized controlled trial. Lancet 2018; 391: 748.

89. Goldberg H. et al. Does perioperative chemotherapy improve survival in upper tract urothelial carcinoma? A population based analysis. Oncotarget 2018; 9: 18797.

90. Necchi A. et al. Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration. BJU Int 2018; 121: 252.

91. Fujita K. et al. Adjuvant chemotherapy improves survival of patients with high-risk upper urinary tract urothelial carcinoma: a propensity score-matched analysis. BMC Urol 2017; 17: 110.

92. Birtle A.J. et al. Results of POUT: A phase III randomized trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC). J Clin Oncol 2018; 36: 407.

93. Faltas B.M. et al. Metastasectomy in older adults with urothelial carcinoma: Population-based analysis of use and outcomes. Urol Oncol 2018; 36: 9. e11.

94. Ploussard G. et al. Conditional survival after radical nephroureterectomy for upper tract carcinoma. Eur Urol 2015; 67: 803.

95. Shigeta K. et al. The conditional survival with time of intravesical recurrence of upper tract urothelial carcinoma. J Urol 2017; 198: 1278.

96. Sudakoff G.S., et al. Multidetector computerized tomography urography as the primary imaging modality for detecting urinary tract neoplasms in patients with asymptomatic hematuria. J Urol, 2008. 179: 862.

97. Wang L.J., et al. Diagnostic accuracy of transitional cell carcinoma on multidetector computerized tomography urography in patients with gross hematuria. J Urol, 2009. 181: 524.

98. Wang L.J., et al. Multidetector computerized tomography urography is more accurate than excretory urography for diagnosing transitional cell carcinoma of the upper urinary tract in adults with hematuria. J Urol, 2010. 183: 48.

99. Jinzaki M., et al. Comparison of CT urography and excretory urography in the detection and localization of urothelial carcinoma of the upper urinary tract. AJR Am J Roentgenol, 2011. 196: 1102.

100. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. Kamat A.M.¹, Bellmunt J.², Galsky M.D. J Immunother Cancer. 2017 Aug 15; 5(1): 68. doi: 10.1186/s40425-017-0271-0.

101. Czito B., et al. Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. J Urol, 2004. 172(4 Pt 1): 1271. https://www.ncbi.nlm.nih.gov/pubmed/15371822

102. Rev Urol. 2006 Spring; 8(2): 61 - 70. Treatment of Upper Tract Urothelial Carcinoma: A Review of Surgical and Adjuvant Therapy Kalyan C Latchamsetty, MD and Christopher R Porter, MDCancer Med. 2018 Dec; 7(12): 6112 - 6123. Validation of the preoperative controlling nutritional status score as an independent predictor in a large Chinese cohort of patients with upper tract urothelial carcinoma Hang Xu, 1 Ping Tan, 1 Xi Jin.

103. Gopalakrishna A., Longo T.A., Fantony J.J., et al. Lifestyle factors and health-related quality of life in bladder Cancer survivors: a systematic review. J Cancer Surviv 2016; 10: 874 - 82. doi: 10. 1007/s11764-016-0533-8

104. Maloney, I., Parker, D. C., Cookson, M. S., & Patel, S. (2017). Bladder Cancer Recovery Pathways: A Systematic Review. Bladder cancer (Amsterdam, Netherlands), 3(4), 269 - 281.

105. Silverdale N., Wherry M., Roodhouse A. Massage and reflexology for post-operative cancer cystectomy patients: Evaluation of a pilot service. Complement Ther Clin Pract. 2019 Feb; 34: 109 - 112.

106. 49 Stout N.L., Baima J., Swisher A.K., Winters-Stone K.M., Welsh J. A. Systematic Review of Exercise Systematic Reviews in the Cancer Literature (2005 - 2017). PM R. 2017 Sep; 9(9S2): S347 - S384.

107. Kinkead B., Schettler P.J., Larson E.R., Carroll D., Sharenko M., Nettles J., Edwards S.A., Miller A.H.1, Torres M.A., Dunlop B.W., Rakofsky J.J., Rapaport M.H. Massage therapy decreases cancer-related fatigue: Results from a randomized early phase trial. Cancer. 2018 Feb 1; 124(3): 546 - 554.

108. Streckmann F., Zopf E.M., Lehmann H.C., et al: Exercise intervention studies in patients with peripheral neuropathy: a systematic review. Sports Med 2014; 44: 1289 - 1304.

109. Kleckner I.R., Kamen C., Gewandter J.S., et al: Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Support Care Cancer 2018; 26: 1019 - 1028.

110. Muzi J.L., Look R.M., Turner C., Gardiner S.K., Wagie T., Douglas J., Sorenson L., Evans L., Kirchner S., Dashkoff C., Garrett K., Johnson N. Low-level laser therapy for chemotherapy-induced peripheral neuropathy. Journal of Clinical Oncology 30, no. 15_suppl (May 2012) 9019 - 9019.

111. 54 Rick O., von Hehn U., Mikus E., Dertinger H., & Geiger G. (2016). Magnetic field therapy in patients with cytostatics-induced polyneuropathy: A prospective randomized placebo-controlled phase-III study. Bioelectromagnetics, 38(2), 85 - 94.

112. A., S.A., Tan E. Effects of transcutaneous electrical nerve stimulation in patients with peripheral and central neuropathic pain. J Rehabil Med. 2014 May; 46(5): 454 - 60. doi: 10.2340/16501977-1271.

113. Oberoi S., Zamperlini-Netto G., Beyene J., Treister N.S., Sung L. Effect of prophylactic low level laser therapy on oral mucositis: a systematic review and meta-analysis. Send to PLoS One. 2014 Sep 8; 9(9): e107418.

114. Ross M., Fischer-Cartlidge E. Scalp Cooling: A Literature Review of Efficacy, Safety, and Tolerability for Chemotherapy-Induced Alopecia. Clin J Oncol Nurs. 2017 Apr 1; 21(2): 226 - 233. doi: 10.1188/17.CJON.226-233

115. Visser, Wilhelmina S. et al. Pelvic floor rehabilitation to improve functional outcome after a low anterior resection: a systematic review. Annals of coloproctology vol. 30,3 (2014): 109 - 14.

116. Avci, P., Gupta, G. K., Clark, J., Wikonkal, N., & Hamblin, M. R. (2013). Low-level laser (light) therapy (LLLT) for treatment of hair loss. Lasers in surgery and medicine, 46(2), 144 - 51.

117. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2019 Update [Электронный источник]//European Association of Urology [сайт]. URL: https://uroweb.org/guideline/upper-urinary-tract-urothelial-cell-carcinoma/ (дата обращения: 20.11.2019).

118. Redrow G.P., et al. Upper Urinary Tract Carcinoma In Situ: Current Knowledge, Future Direction. J Urol, 2017. 197: 287.

119. Giannarini G., et al. Antegrade perfusion with bacillus Calmette-Guerin in patients with non-muscleinvasive urothelial carcinoma of the upper urinary tract: who may benefit? Eur Urol, 2011. 60: 955.

120. Pollard M.E., Levinson A.W., Shapiro E.Y., et al: Comparison of 3 Upper Tract

121. Anticarcinogenic Agent Delivery Techniques in an Ex Vivo Porcine Model. Urology 2013; 82: 1451. e1-1451. e6.

122. Roupret M., Babjuk M., Comperat E., et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. Eur Urol 2018; 73: 111 - 122. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28867446.

123. Mandalapu R.S., Remzi M., de Reijke T.M., et al. Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of low-risk upper tract urothelial carcinoma. World J Urol 2017; 35: 355 - 365. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27233780.

124. O"Brien T., Ray E., Singh R., et al. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). Eur Urol 2011; 60: 703 - 710. Available at: https://www.ncbi.nlm.nih.gov/pubmed/21684068.

125. Ito A., Shintaku I., Satoh M., et al. Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial. J Clin Oncol 2013; 31: 1422 - 1427. Available at: https://www.ncbi.nlm.nih.gov/pubmed/23460707.

126. Miyamoto K., Ito A., Wakabayashi M., et al. A Phase III trial of a single early intravesical instillation of pirarubicin to prevent bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma (JCOG1403, UTUC THP Phase III). Jpn J Clin Oncol 2018; 48: 94 - 97. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29136187.

127. Kim D.K., Lee J.Y., Kim J.W., et al. Effect of neoadjuvant chemotherapy on locally advanced upper tract urothelial carcinoma: A systematic review and meta-analysis. Crit Rev Oncol Hematol 2019; 135: 59 - 65. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30819447.

128. Audenet F., et al. The role of chemotherapy in the treatment of urothelial cell carcinoma of the upper urinary tract (UUT-UCC). Urol Oncol, 2013. 31: 407.

129. Kaag M.G., et al. Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol, 2010. 58: 581. https://www.ncbi.nlm.nih.gov/pubmed/20619530

130. Lane B.R., et al. Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. Cancer, 2010. 116: 2967. https://www.ncbi.nlm.nih.gov/pubmed/20564402

131. Goldberg H., et al. Does perioperative chemotherapy improve survival in upper tract urothelial carcinoma? A population based analysis. Oncotarget, 2018. 9: 18797. https://www.ncbi.nlm.nih.gov/pubmed/29721162.

132. Necchi A., et al. Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration. BJU Int, 2018. 121: 252. https://www.ncbi.nlm.nih.gov/pubmed/28940605

133. Fujita K., et al. Adjuvant chemotherapy improves survival of patients with high-risk upper urinary tract urothelial carcinoma: a propensity score-matched analysis. BMC Urol, 2017. 17: 110. https://www.ncbi.nlm.nih.gov/pubmed/29195499

134. Seisen T., et al. Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. J Clin Oncol, 2017. 35: 852. https://www.ncbi.nlm.nih.gov/pubmed/28045620].

135. Birtle A.J., et al. Results of POUT: A phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC). J Clin Oncol, 2018. 36: 407. http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.6_suppl.407

136. Hahn A.W., et al. Effect of Adjuvant Radiotherapy on Survival in Patients with Locoregional Urothelial Malignancies of the Upper Urinary Tract. Anticancer Res, 2016. 36: 4051. https://www.ncbi.nlm.nih.gov/pubmed/27466512

137. Huang Y.C., et al. Adjuvant radiotherapy for locally advanced upper tract urothelial carcinoma. Sci Rep, 2016. 6: 38175. https://www.ncbi.nlm.nih.gov/pubmed/27910890

138. Czito B., et al. Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. J Urol, 2004. 172(4 Pt 1): 1271. https://www.ncbi.nlm.nih.gov/pubmed/15371822

139. Shigeta K., et al. The Conditional Survival with Time of Intravesical Recurrence of Upper Tract Urothelial Carcinoma. J Urol, 2017. 198: 1278. https://www.ncbi.nlm.nih.gov/pubmed/28634017

140. Bellmunt J., et al. New therapeutic challenges in advanced bladder cancer. Semin Oncol 2012. 39: 598.

141. Sternberg C.N., et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 2001. 19: 2638.

142. Galsky M.D., et al. Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. J Clin Oncol 2011. 29: 2432.

143. De Santis M., et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986. J Clin Oncol 2009. 27: 5634.

144. Sudakoff G.S., et al. Multidetector computerized tomography urography as the primary imaging modality for detecting urinary tract neoplasms in patients with asymptomatic hematuria. J Urol, 2008. 179: 862. https://www.ncbi.nlm.nih.gov/pubmed/18221955

145. Wang L.J., et al. Diagnostic accuracy of transitional cell carcinoma on multidetector computerized tomography urography in patients with gross hematuria. J Urol, 2009. 181: 524. https://www.ncbi.nlm.nih.gov/pubmed/19100576

146. Wang L.J., et al. Multidetector computerized tomography urography is more accurate than excretory urography for diagnosing transitional cell carcinoma of the upper urinary tract in adults with hematuria. J Urol, 2010. 183: 48. https://www.ncbi.nlm.nih.gov/pubmed/19913253

147. Jinzaki M., et al. Comparison of CT urography and excretory urography in the detection and localization of urothelial carcinoma of the upper urinary tract. AJR Am J Roentgenol, 2011. 196: 1102. https://www.ncbi.nlm.nih.gov/pubmed/21512076

148. Rosenthal D.L., et al. The Paris System for Reporting Urinary Cytology. 2016, Switzerland 2016.

149. Chen A.A., et al. Is there a role for FISH in the management and surveillance of patients with upper tract transitional-cell carcinoma? J Endourol, 2008. 22: 1371. https://www.ncbi.nlm.nih.gov/pubmed/18578665

150. Johannes J.R., et al. Voided urine fluorescence in situ hybridization testing for upper tract urothelial carcinoma surveillance. J Urol, 2010. 184: 879. https://www.ncbi.nlm.nih.gov/pubmed/20643443

151. Cowan N.C., et al. Multidetector computed tomography urography for diagnosing upper urinary tract urothelial tumour. BJU Int, 2007. 99: 1363. https://www.ncbi.nlm.nih.gov/pubmed/17428251

152. Lee K.S., et al. MR urography versus retrograde pyelography/ureteroscopy for the exclusion of upper urinary tract malignancy. Clin Radiol, 2010. 65: 185. https://www.ncbi.nlm.nih.gov/pubmed/20152273

153. Cutress M.L., et al. Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review. BJU Int, 2012. 110: 614. https://www.ncbi.nlm.nih.gov/pubmed/22471401

154. Roupret M., et al. Upper urinary tract transitional cell carcinoma: recurrence rate after percutaneous endoscopic resection. Eur Urol, 2007. 51: 709. https://www.ncbi.nlm.nih.gov/pubmed/16911852

155. Song Y. S., Cho J. S., Cho K. S., Doo S. H., Chung B. H., Kim S. J., ... Hong S. J. (2010). Efficacy of Adjuvant Gemcitabine-Cisplatin Chemotherapy: A Comparative Study between Locally Advanced Transitional Cell Carcinoma of the Bladder and Upper Urinary Tract. Urologia Internationalis, 85(1), 47 - 51. doi:10.1159/000296294

156. Bellmunt J., de Wit R., Albanell J., & Baselga J. (2001). A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer. European Journal of Cancer, 37(17), 2212 - 2215. doi:10.1016/s0959-8049(01)00295-7

157. https://rosoncoweb.ru/standarts/RUSSCO/2015/28.pdf

158. Bellmunt J., de Wit R., Vaughn D.J., et al. on behalf of the keynote-045 investigators. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017; 376: 1015 - 26. doi: 10.1056/NEJMoa1613683.

159. Sharma P., Retz M., Siefker-Radtke A., et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017; 18: 312 - 22. doi: 10.1016/S1470-2045(17)30065-7.

160. Rosenberg J.E., Hoffman-Censits J., Powles T., et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016; 387: 1909 - 20. doi: 10.1016/S0140-6736(16)00561-4.

161. Приказ от 24 марта 2016 г. N 179н министерства здравоохранения Российской Федерации О Правилах проведения патолого-анатомических исследований http://pravo.gov.ru/proxy/ips/?doc_itself=&backlink=1&nd=102396069&page=1&rdk=0#I0

162. Приказ от 10 мая 2017 г. N 203н Министерства здравоохранения Российской Федерации "Об утверждении критериев оценки качества медицинской помощи".